Stability evaluation of Tc-99m radiolabeled GRPr antagonist with amino acid chelators
Article
First Online:
- 22 Downloads
Abstract
In order to select a chelator with excellent stability, easier radiolabeling process and low cost, GRPr antagonist RM26 with the amino acid based chelator was radiolabeled with technetium-99m. The stability of the radiolabeled peptides in PBS, serum as well as in the presence of excess cysteine was compared.
Keywords
Technetium-99m Radiopeptide RM26 KGC N3SNotes
Acknowledgements
This research is financially supported by Science and Technology Development of Foundation of China Academy of Engineering Physics (2014A0301011) and China National Natural Science Foundation (21571164).
References
- 1.Schroeder RPJ (2009) Peptide receptor imaging of prostate cancer with radiolabeled bombesin analogues. Methods 48:200–204CrossRefGoogle Scholar
- 2.Mansi R (2013) Targeting GRPR in urological cancers-from basic research to clinical application. Nat Rev Urol 10:235–244CrossRefGoogle Scholar
- 3.Carsten K (2013) Hybrid bombesin analogues: combining an agonist and an antagonist in defined distances for optimized tumor targeting. J Am Chem Soc 135:16793–16796CrossRefGoogle Scholar
- 4.Mansi R (2011) Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 15:5240–5249CrossRefGoogle Scholar
- 5.Ginj M (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 103:16436–16441CrossRefGoogle Scholar
- 6.Ginj M (2006) Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. PNAS 103:16436–16441CrossRefGoogle Scholar
- 7.Kristell LSC (2014) Preclinical comparison of Al18F and 68Ga labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. J Nucl Med 12:2050–2056Google Scholar
- 8.Mansi R (2016) Bombesin-targeted PET of prostate cancer. J Nucl Med 10:67S–72SCrossRefGoogle Scholar
- 9.Shirmardi SP (2011) Synthesis and evaluation of a new bombesin analog labeled with 99mTc as a GRP receptor imaging agent. J Radioanal Nucl Chem 288:327–335CrossRefGoogle Scholar
- 10.Monroy-Guzman F (2003) Effect of Zr: Mo ratio on 99mTc generator performance based on zirconium molybdate gels. Appl Radiat Isot 59:27–34CrossRefGoogle Scholar
- 11.Monroy-Guzman F (2012) Production optimization of 99Mo/99mTc zirconium molybate gel generators at semi-automatic device: DISIGEG. Appl Radiat Isot 70:103–111CrossRefGoogle Scholar
- 12.Abram U (2006) Technetium and rhenium—coordination chemistry and nuclear medical applications. J Braz Chem Soc 17:1486–1500CrossRefGoogle Scholar
- 13.Lei K (1996) Technetium-99m antibodies labeled with MAG3 and SHNH: an in vitro and animal in vivo comparison. Nucl Med Biol 23:917–922CrossRefGoogle Scholar
- 14.Zhang Y (2000) Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA. Eur J Nucl Med 27:1700–1707CrossRefGoogle Scholar
- 15.Vanderheyden JL (2006) Evaluation of 99mTc-MAG3-annexin V: influence of the chelate on in vitro and in vivo properties in mice. Nucl Med Biol 33:135–144CrossRefGoogle Scholar
- 16.Hjelstuen OK (1998) 3′-99mTc labeling and biodistribution of a CAPL antisense oligodeoxynucleotide. Nucl Med Biol 25:651–657CrossRefGoogle Scholar
- 17.Verduyckt T (2003) Identity confirmation of 99mTc-MAG3, 99mTc-Sestamibi and 99mTc-ECD using radio-LC-MS. J Pharmaceut Biomed. 32:669–678CrossRefGoogle Scholar
- 18.Kan W (2016) Coordination investigation of rhenium with MAG3 using LC-MS and UV spectrometer and the simple radiolabelling process. J Radioanal Nucl Chem 310:695–702CrossRefGoogle Scholar
Copyright information
© Akadémiai Kiadó, Budapest, Hungary 2018